0000000000020968

AUTHOR

Juan Montoro

0000-0003-0024-8068

showing 32 related works from this author

Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality fr…

2018

Abstract Risk factors (RFs) and mortality data of community‐acquired respiratory virus (CARVs) lower respiratory tract disease (LRTD) with concurrent pulmonary co‐infections in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is scarce. From January 2011 to December 2017, we retrospectively compared the outcome of allo‐HSCT recipients diagnosed of CARVs LRTD mono‐infection (n = 52, group 1), to those with viral, bacterial, or fungal pulmonary CARVs LRTD co‐infections (n = 15, group 2; n = 20, group 3, and n = 11, group 4, respectively), and with those having bacterial pneumonia mono‐infection (n = 19, group 5). Overall survival (OS) at day 60 after bronchoalveol…

Male0301 basic medicinemedicine.medical_treatmentcommunity acquired respiratory virusHematopoietic stem cell transplantationBronchoalveolar LavageGastroenterology0302 clinical medicineRisk Factorsrespiratory virus co‐infectionsLungRespiratory Tract Infectionsmedicine.diagnostic_testRespiratory tract infectionsCoinfectionHematopoietic Stem Cell TransplantationMiddle AgedCommunity-Acquired InfectionsInfectious Diseasesmedicine.anatomical_structureVirusesvirus-bacterial mixed infectionsRespiratory virusFemaleOriginal Articlerespiratory virus co-infectionsBronchoalveolar Lavage FluidAdultmedicine.medical_specialtyvirus‐bacterial mixed infections030106 microbiologyContext (language use)CMV DNAemiaAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansTransplantation Homologousallogeneic hematopoietic stem cell transplantationAgedRetrospective StudiesTransplantationLungBacteriabusiness.industryFungiBacterial pneumoniaOriginal Articlesmedicine.diseaseTransplantationBronchoalveolar lavagebusinessimmunodeficiency score index030215 immunology
researchProduct

Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic…

2020

Torque Teno virus (TTV) DNA load in blood may act as a marker of immune competence after allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). Conflicting data have been reported as to the value of this biomarker for anticipating acute Graft-versus-host disease (aGvHD) occurrence. Here, we hypothesized that quantitation of TTV DNA load in stool specimens early after allo-HSCT could be used to identify patients at high risk of acute intestinal graft-versus-host disease (aIGvHD). In this prospective two-center study we recruited a total of 83 non-consecutive adult patients undergoing allo-HSCT. The study period comprised the first 120 days after allo-HSCT. TTV DNA was quantita…

Adultmedicine.medical_specialtyTorque teno virusmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationDisease030230 surgeryGastroenterology03 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicineHumansIn patientProspective StudiesTorque teno virusTransplantationbusiness.industryHematopoietic Stem Cell TransplantationViral LoadDNA Virus InfectionsTorque teno virus DNAKineticssurgical procedures operativeInfectious DiseasesDNA ViralBiomarker (medicine)030211 gastroenterology & hepatologyIntestinal Graft Versus Host DiseasebusinessTransplant Infectious Disease
researchProduct

Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell tra…

2020

BACKGROUND: Enterovirus/rhinoviruses (EvRh) are the most common cause of respiratory virus infections in recipients of allogeneic stem cell transplantation (allo-HSCT).; OBJECTIVE: We sought to analyze the value of the immunodeficiency scoring index (ISI) in predicting lower respiratory tract disease (LRTD) progression and mortality in a prospective cohort of consecutive adult (> 16 years) allo-HSCT recipients with EvRh infection from December 1 2013 to December 1 2019 at two Spanish transplant centers.; RESULTS: We included 234 allo-HSCT recipients with 383 EvRh episodes. Out of 383 EvRh episodes, 98 (25%) had LRTD. Multivariate logistic regression analysis identified three independent fac…

AdultMalemedicine.medical_specialtyAdolescentRhinovirusmedicine.medical_treatmentHematopoietic stem cell transplantationcommunity acquired respiratory virus030230 surgerymedicine.disease_cause03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineallogeneic stem celltrasplantationmedicineHumansTransplantation HomologousProspective StudiesProspective cohort studyRespiratory Tract InfectionsImmunodeficiencyimmunodeficiency scoring indexAgedRetrospective StudiesTransplantationPicornaviridae InfectionsRespiratory tract infectionsbusiness.industryHematopoietic Stem Cell TransplantationImmunologic Deficiency SyndromesRespiratory infectionMiddle Agedmedicine.diseaseTransplantationInfectious DiseasesrhinovirusROC CurveSpainMultivariate AnalysisRespiratory virus030211 gastroenterology & hepatologyFemaleRhinovirusbusiness
researchProduct

An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus…

2021

It is uncertain whether gastrointestinal (GI) infection caused by viral and bacterial pathogens may predispose to gastrointestinal acute Graft-versus-host disease (aGvHD-GI) in allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). We investigated the potential association between detection of enteropathogenic viruses or bacteria in stools and subsequent occurrence of aGvHD-GI in a cohort of 121 allo-HSCT patients. Eighty-six out of 121 patients (71%) had acute diarrhea and underwent screening for primary GI pathogens by molecular diagnostic methods. One or more GI pathogens were detected in 27 out of the 86 patients with diarrhea (31.3%). Specifically, Clostridioides diffici…

AdultMalemedicine.medical_specialtyAdolescentGastrointestinal Diseasesmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationmedicine.disease_causeGastroenterologyAstrovirus03 medical and health sciencesFecesYoung Adult0302 clinical medicineVirologyInternal medicineRotavirusparasitic diseasesmedicineHumans030212 general & internal medicineProspective StudiesAgedProportional Hazards ModelsbiologyBacteriabusiness.industryCampylobacterHematopoietic Stem Cell TransplantationSapovirusBacterial InfectionsClostridium difficileMiddle Agedbiology.organism_classificationVirologyDiarrheaInfectious DiseasesVirus DiseasesAcute DiseaseVirusesNorovirus030211 gastroenterology & hepatologyFemaleDisease Susceptibilitymedicine.symptombusinessJournal of medical virologyREFERENCES
researchProduct

INFECTIOUS COMPLICATIONS AFTER UMBILICAL CORD-BLOOD TRANSPLANTATION FROM UNRELATED DONORS

2016

Umbilical cord-blood (UCB) is a well-recognized alternative source of stem cells for unrelated donor hematopoietic stem cell transplantation (HSCT). As compared with other stem cell sources from adult donors, it has the advantages of immediate availability of cells, absence of risk to the donor and reduced risk of graft-versus-host disease despite donor-recipient HLA disparity. However, the use of UCB is limited by the delayed post-transplant hematologic recovery due, at least in part, to the reduced number of hematopoietic cells in the graft and the delayed or incomplete immune reconstitution. As a result, severe infectious complications continue to be a leading cause of morbidity and mort…

lcsh:RC633-647.5Umbilical Cord Blood Transplantationbusiness.industryIncidence (epidemiology)medicine.medical_treatmentReview Articlelcsh:Diseases of the blood and blood-forming organsHematologyHuman leukocyte antigenDiseaseHematopoietic stem cell transplantation: umbilical cord-blood transplantation infectious bacterial fungal viral03 medical and health sciencesHaematopoiesisfluids and secretions0302 clinical medicineInfectious DiseasesImmune system030220 oncology & carcinogenesisImmunologymedicineStem cellbusiness030215 immunologyMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneum…

2019

Highlights • CMV DNA is frequently detected in BAL fluid specimens from allo-HSCT. • CMV DNA detection in BAL fluids is comparable across pneumonia etiologies. • CMV DNA loads in BAL fluids are comparable across pneumonia etiologies. • CMV DNA load in BAL may predict attributable-pneumonia mortality.

Male0301 basic medicineDna loadCMV pneumoniaCytomegalovirusmedicine.disease_causechemistry.chemical_compound0302 clinical medicinePre-emptive antiviral therapyMedicine030212 general & internal medicineCMV DNA in BALAged 80 and overmedicine.diagnostic_testHematopoietic Stem Cell Transplantationvirus diseasesrespiratory systemMiddle AgedViral LoadVirus SheddingInfectious DiseasesCytomegalovirus InfectionsFemaleAllogeneic hematopoietic stem cell transplantBronchoalveolar Lavage FluidAdultMicrobiology (medical)Pneumonia Viral030106 microbiologyCMV DNAemiaArticle03 medical and health sciencesHumansTransplantation HomologousAgedRetrospective Studiesbusiness.industryCMV PneumoniaCytomegalovirusRetrospective cohort studymedicine.diseaseTransplant Recipientsrespiratory tract diseasesPneumoniaBronchoalveolar lavagechemistryDNA ViralImmunologybusinessDNAJournal of Infection
researchProduct

Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: A cross-sectional prospective observational…

2018

Abstract Background Vaccination is the primary method for preventing influenza respiratory virus infection (RVI). Although the influenza vaccine is able to achieve serological responses in some allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, its clinical benefits are still uncertain. Methods In this prospective, cross-sectional study, we retrospectively analyzed the effect of inactivated trivalent influenza vaccination on the prevalence of influenza RVI in a consecutive cohort of 136 allo-HSCT adult recipients who developed 161 RVI over 5 flu seasons (from 2013 to 2018). Respiratory viruses in upper– and/or lower–respiratory tract specimens were tested using multi…

0301 basic medicineMalemedicine.medical_treatmentHematopoietic stem cell transplantationinfluenza virus0302 clinical medicineRisk FactorsOdds RatioMedicine030212 general & internal medicineProspective StudiesArticles and CommentariesImmunodeficiencybiologyVaccinationHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedVaccinationHospitalizationInfectious DiseasesTreatment OutcomeInfluenza VaccinesCohortFemaleMicrobiology (medical)Adultmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyOrthomyxoviridae03 medical and health sciencesImmunocompromised HostYoung AdultInternal medicineInfluenza HumanHumansTransplantation Homologousallogeneic hematopoietic stem cell transplantationRisk factorAgedRetrospective Studiescommunity-acquired respiratory virusbusiness.industryOdds ratiomedicine.diseasebiology.organism_classificationCross-Sectional StudiesSpainbusinessimmunodeficiency score index
researchProduct

Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens

2020

Microbiology (medical)Simplexvirusfood.ingredientbusiness.industryPneumonia PneumocystisDNAPneumocystis cariniiReal-Time Polymerase Chain Reactionmedicine.diseaseVirologyImmunocompromised Hostchemistry.chemical_compoundPneumoniaInfectious DiseasesfoodReal-time polymerase chain reactionchemistryPneumocystis jirovecii DNAHumansSimplexvirusMedicineClinical significanceRespiratory systembusinessDNAJournal of Infection
researchProduct

The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem…

2019

Highlights • Rapid detection methods used as first diagnostic test for CARVs may delayed the start of antiviral therapy in a significant number of influenza and RSV cases. • Syndromic multiplex RT-PCR-based prospective clinical CARV survey in allo-HCT recipients translates into a lower mortality rate as compared to standard clinical practice based on RSV and influenza virus rapid detection test. • We found that donor/recipient HLA mismatch, CARV LRTD and high-risk ISI were also associated with higher mortality.

Prospective respiratory virus surveillance program0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.medical_treatment030106 microbiologyHematopoietic stem cell transplantationRespiratory syncytial virusArticleParainfluenza virus03 medical and health sciences0302 clinical medicineStudy reportCommunity-acquired respiratory virusInternal medicinemedicineHumansProspective Studies030212 general & internal medicineStage (cooking)Prospective cohort studyRespiratory Tract InfectionsRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyInfluenzaInfectious Diseasesmedicine.anatomical_structureRespiratory virus infectionVirusesAllogeneic hematopoietic stem cell transplantationRespiratory virusbusinessLower mortalityImmunodeficiency score indexRespiratory tractJournal of Infection
researchProduct

SARS‐CoV ‐2‐reactive antibody detection after SARS‐CoV ‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the S…

2021

This is a multicenter prospective observational study which included a large cohort (n = 397) of allogeneic (allo-HSCT) (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3 to 6 weeks after complete SARS-CoV-2 vaccination from February 1st 2021 to July 20th 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia <1x109 /mL [Odds ratio (OR…

Oncologymedicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentHematopoietic stem cellHematologyDiseaseOdds ratioHematopoietic stem cell transplantationmedicine.diseaseLymphomaCell therapyVaccinationmedicine.anatomical_structureInternal medicinemedicinebiology.proteinAntibodybusinessAmerican Journal of Hematology
researchProduct

Advances in haploidentical stem cell transplantation for hematologic malignancies

2016

One of the most important advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the use of alternative donors and cell sources, such as haploidentical transplants (haplo-HSCT) from family donors. Several approaches have been developed to overcome the challenging bidirectional alloreactivity. We discuss these approaches, including ex vivo T-cell-depleted grafts with megadose of CD34(+) cells, not requiring immunosuppression after allogeneic transplantation for graft-versus-host disease (GVHD) prophylaxis, and other strategies using unmanipulated T-cell-replete grafts with intensive immunosuppression or post-transplantation cyclophosphamide to minimize the GVHD. We als…

Cancer ResearchAllogeneic transplantationmedicine.medical_treatmentGraft vs Host DiseaseContext (language use)Hematopoietic stem cell transplantationT-Lymphocytes RegulatoryLymphocyte DepletionDonor Selection03 medical and health sciences0302 clinical medicineReceptors KIRHLA AntigensmedicineHumansCyclophosphamideDonor selectionbusiness.industryHistocompatibility TestingHematopoietic Stem Cell TransplantationImmunosuppressionHematologyAllograftsTransplantationTreatment Outcomesurgical procedures operativeClinical Trials Phase III as TopicOncologyHematologic Neoplasms030220 oncology & carcinogenesisTransplantation HaploidenticalImmunologyStem cellUnrelated DonorsbusinessImmunosuppressive AgentsEx vivo030215 immunologyLeukemia &amp; Lymphoma
researchProduct

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myelo…

2022

Post-transplant cyclophosphamide (PTCy) has emerged as a promising graft-versus-host disease (GvHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no studies have reported the efficacy of a GvHD prophylaxis based on PTCy with sirolimus (Sir-PTCy) in patients with acute myeloid leukemia (AML). In this retrospective study, we analyze the use of sirolimus in combination with PTCy, with or without mycophenolate mofetil (MMF), on 242 consecutive adult patients with AML undergoing a myeloablative first allo-HSCT from different donor types, in three European centers between January 2017 and December 2020. Seventy-seven (32%) patients received allo-HSCT from…

AdultSirolimusTransplantationBLOODTransplantation ConditioningCONDITIONING INTENSITYGVHD PROPHYLAXISHematopoietic Stem Cell TransplantationGraft vs Host Disease1ST COMPLETE REMISSIONHematologyMycophenolic AcidOPEN-LABELDIAGNOSISPatologiaHEMATOLOGIC MALIGNANCIESEUROPEAN-SOCIETYLeukemia Myeloid AcuteRISK INDEXHumansMARROW-TRANSPLANTATIONUnrelated DonorsCyclophosphamideRetrospective StudiesBone marrow transplantation
researchProduct

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia

2017

We retrospectively compared the clinical outcomes of adults with acute leukemia who received single-unit umbilical cord blood (UCB) transplantation (sUCBT) (n = 135) or stem cell transplant using coinfusion of a UCB graft with CD34+ cells from a third-party donor (Haplo-Cord) (n = 72) at different institutions within the Grupo Espanol de Trasplante Hematopoyetico. In multivariable analysis, patients in the Haplo-Cord group showed more rapid neutrophil (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.5-3.3; P < .001) and platelet recovery (HR, 1.6; 95% CI, 1.2-2.3; P = .015) and lower incidence of chronic graft-versus-host disease (GVHD) (relative risk, 0.5; 95% CI, 0.3-0.8; P = .01)…

Acute leukemiamedicine.medical_specialtyendocrine systemTransplantationbusiness.industryHazard ratioMyeloid leukemiaContext (language use)Hematologymedicine.diseaseUmbilical cordGastroenterologyTransplantation03 medical and health sciencesLeukemia0302 clinical medicinemedicine.anatomical_structureGraft-versus-host disease030220 oncology & carcinogenesisInternal medicineImmunologyMedicinebusiness030215 immunology
researchProduct

Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR ass…

2013

Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center

AdultMaleAdolescentPcr assayCongenital cytomegalovirus infectionCytomegalovirusReal-Time Polymerase Chain ReactionSingle CenterHumansMedicineDna viralAgedMonitoring PhysiologicRetrospective StudiesTransplantationbusiness.industryAntiviral therapyvirus diseasesHematologyCmv dnaemiaAllo sctMiddle AgedAllograftsmedicine.diseaseVirologyReal-time polymerase chain reactionHematologic NeoplasmsCytomegalovirus InfectionsDNA ViralImmunologyFemalebusinessStem Cell TransplantationBone Marrow Transplantation
researchProduct

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell tra…

2019

Abstract Background There is growing evidence that community‐acquired respiratory virus (CARV) increases the risk of pulmonary invasive fungal disease (IFD) in the allogeneic hematopoietic stem cell transplantation (allo‐HSCT) setting. To date, there is a lack of knowledge regarding the risk factors (RFs), as well as the most critical period for subsequent onset of IFD after CARV infections in allo‐HSCT recipients. Methods In this prospective longitudinal observational CARV survey, we analyzed the effect of CARV on subsequent IFD development in 287 adult allo‐HSCT recipients diagnosed with 597 CARV episodes from December 2013 to December 2018. Multiplex PCR panel assays were used to test CA…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentHematopoietic stem cell transplantation030230 surgeryYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsRespiratory virus infectionSurveys and QuestionnairesInternal medicinemedicineHumansTransplantation HomologousLongitudinal StudiesProspective Studiesallogeneic hematopoietic stem cell transplantationRespiratory systemRespiratory Tract InfectionsAgedcommunity-acquired respiratory virusTransplantationcommunity‐acquired respiratory virusbusiness.industryIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationOriginal Articlesinvasive pulmonary fungal diseaseOdds ratioMiddle AgedTransplant Recipientsinvasive AspergillosisConfidence intervalCommunity-Acquired InfectionsInfectious DiseasesInvasive fungal diseaseRespiratory virusFemaleOriginal Article030211 gastroenterology & hepatologybusinessInvasive Fungal Infectionsimmunodeficiency score indexTransplant Infectious Disease
researchProduct

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Trans…

2020

In this prospective randomized study, we compared the outcomes of single-unit umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (haplo-SCT) with post-transplantation cyclophosphamide (PTCy) in adults with hematologic malignancies. All patients received a myeloablative conditioning (MAC) regimen consisting of thiotepa, busulfan, and fludarabine, with antithymocyte globulin (ATG) added for UCBT recipients. Nineteen patients were randomized to UCBT and the other 26 to haplo-HSCT. Four patients (15%) allocated to the haplo-HSCT arm lacked a suitable donor and were crossed over to the UCBT arm. Finally, 23 underwent UCBT and 22 underwent haplo…

Adultmedicine.medical_specialtyendocrine systemHematologic malignancyTransplantation ConditioningHaploidentical transplantationGraft vs Host DiseaseContext (language use)ThioTEPAGastroenterologyMAC Regimen03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCumulative incidenceProspective StudiesTransplantationAllogeneic stem cell transplantation clinical trial Alternative donor transplantation Haploidentical transplantation Hematologic malignancy Umbilical cord blood transplantationUmbilical cord blood transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyAlternative donor transplantationFludarabineTransplantationRegimenAllogeneic stem cell transplantation clinical trialsurgical procedures operative030220 oncology & carcinogenesisHematologic NeoplasmsCord Blood Stem Cell TransplantationNeoplasm Recurrence LocalbusinessBusulfan030215 immunologymedicine.drug
researchProduct

Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.

2020

In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF) have been hardly investigated. This retrospective study included all consecutive patients receiving an allogeneic hematopoietic stem cell transplantation for myeloid malignancies (January 2009-2017) conditioned with either TBF or BF and receiving SIR-TAC. Patients receiving TBF presented higher non-relapse mortality (31.6 vs 12.3%,p = .01), along with shorter overall survival …

Cancer Researchmedicine.medical_specialtyTransplantation ConditioningUrologyGraft vs Host Diseasechemical and pharmacologic phenomenaThioTEPAReduce intensity conditioningsirolimus and tacrolimusgraft vs host disease prophylaxisTacrolimus03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesreduce intensity conditioningmedicineHumansHost diseaseBusulfanRetrospective StudiesSirolimusallogeneic hematopoietic cell transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyTacrolimusFludarabinesurgical procedures operativeOncology030220 oncology & carcinogenesisSirolimusFeasibility StudiesConditioningThiotepa-fludarabine-busulfanbusinessThiotepaVidarabineBusulfan030215 immunologymedicine.drug
researchProduct

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogenei…

2021

Objective To compare the efficacy and safety of CD34+ selected ex vivo T-cell depletion (TCD) vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil (PTCy-Sir-MMF) as graft-vs-host disease (GVHD) prophylaxis. Methods We retrospectively included patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) with either TCD (n = 38) or PTCy-Sir-MMF (n = 91). Results Cumulative incidence of neutrophil and platelet recovery was 92% vs 99% (P = .06) and 89% vs 97% (P = .3) in TCD and PTCy-Sir-MMF, respectively. Cumulative incidences of aGHVD grade II-IV, III-IV, and moderate to severe cGVHD were 11% vs 19% (P = .2), 3% vs 2% (P = .9), and 3% vs 36% (P < …

Malemedicine.medical_treatmentT-LymphocytesCD34Graft vs Host DiseaseHematopoietic stem cell transplantationMycophenolateGastroenterologySeverity of Illness IndexLeukocyte Count0302 clinical medicineImmune ReconstitutionPostoperative ComplicationsRecurrenceGVHD prophylaxisAntineoplastic Combined Chemotherapy ProtocolsCumulative incidenceHematopoietic Stem Cell TransplantationT-cell depletionHematologyGeneral MedicineMiddle AgedPrognosisLeukemia Myeloid Acutesurgical procedures operativeTreatment OutcomeT-cell depletion030220 oncology & carcinogenesishematopoietic stem cell transplantationcardiovascular systemFemalemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideAdolescentLymphocyte Depletion03 medical and health sciencesYoung AdultInternal medicinemedicineHumansTransplantation HomologousGVHD prophylaxis T-cell depletion hematopoietic stem cell transplantation post-transplantation cyclophosphamideCyclophosphamideAgedPostoperative CareSirolimuspost-transplantation cyclophosphamidebusiness.industryMycophenolic AcidSirolimusbusinessEx vivoBiomarkers030215 immunologyEuropean journal of haematologyREFERENCES
researchProduct

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

2018

Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p  .0001). PTLD was EBV-positive in 100% of allo-HSCT, in co…

AdultGraft RejectionMaleCancer ResearchPathologymedicine.medical_specialtyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanTransplantation ConditioningAdolescentmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationmedicine.disease_causeSingle Center03 medical and health sciencesYoung Adult0302 clinical medicineEpstein–Barr virus Solid organ transplantation hematopoietic stem cell transplantation immunosuppression post-transplant lymphoproliferative disordershemic and lymphatic diseasesmedicineHumansTransplantation HomologousRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationImmunosuppressionHematologyOrgan TransplantationMiddle Agedmedicine.diseaseEpstein–Barr virusSurvival AnalysisPost transplantLymphoproliferative Disorderssurgical procedures operativeOncology030220 oncology & carcinogenesisFemaleVirus ActivationSolid organLymph NodesbusinessComplication030215 immunology
researchProduct

Glutathione metabolism under the influence of hydroperoxides in the lactating mammary gland of the rat. Effect of glucose and extracellular ATP.

1987

Tert-butyl hydroperoxide decreases GSH and total free glutathione (GSH+2GSSG) contents of acini from lactating mammary glands. The decrease in total free glutathione can be explained by an increase in mixed disulfide formation and by excretion of GSS G to the extracellular medium, and subsequent degradation catalyzed by gamma-glutamyl transpeptidase. Low concentrations of glucose prevented the changes in glutathione levels induced by the peroxide. In the presence of extracellular ATP, glucose did not prevent these changes. However, incubations with the peroxide, did not alter the rate of other metabolic pathways by acini.

GPX1medicine.medical_specialtyGPX3Glutathione reductaseBiophysicsBiologyIn Vitro TechniquesBiochemistryPeroxideExcretionchemistry.chemical_compoundAdenosine TriphosphateMammary Glands Animaltert-ButylhydroperoxidePregnancyInternal medicinemedicineExtracellularAnimalsLactationMolecular BiologyRats Inbred StrainsCell BiologyGlutathioneGlutathionePeroxidesRatsMetabolic pathwayEndocrinologyGlucosechemistryBiochemistryFemaleBioscience reports
researchProduct

A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.

2013

Thymidine phosphorylase (TYMP), an enzyme involved in nucleotide synthesis, has been implicated in critical biological processes such as DNA replication, protection against mutations, and tissue repair. In this work, we retrospectively evaluated the influence of a polymorphism in the TYMP gene (rs112723255; G/A) upon the outcome of 448 patients subjected to allogeneic stem cell transplantation (allo-SCT) from an human leukocyte antigen (HLA)-identical sibling donor. The TYMP genotype of patients correlated with overall survival—carriers of the minor allele (A) being at an increased risk of dying after transplantation (hazard ratio, HR = 1.9; P = 0.004). This effect was mostly due to differe…

OncologyAdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeGraft vs Host DiseaseHuman leukocyte antigenDiseaseBiologyRisk FactorsInternal medicineGenotypemedicineHumansTransplantation HomologousAlleleChildAllelesAgedRetrospective StudiesThymidine PhosphorylasePolymorphism GeneticHistocompatibility TestingSiblingsHazard ratioInfantHematologyMiddle AgedMinor allele frequencyTransplantationSurvival RateChild PreschoolHematologic NeoplasmsImmunologyChronic DiseaseFemaleComplicationStem Cell TransplantationAmerican journal of hematology
researchProduct

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell trans…

2019

The effect of timing of community acquired respiratory virus (CARV) infection after allogeneic hematopoietic stem cell transplant (allo-HCT) is an as yet unsettled issue. We evaluate this issue by including all consecutive allo-HCT recipients with molecularly-documented CARV infection during the first year after transplant. The study cohort was drawn from a prospective longitudinal survey of CARV in allo-HCT recipient having respiratory symptoms conducted from December 2013 to December 2018 at two Spanish transplant centers. Respiratory viruses in upper and/or lower respiratory specimens were tested using multiplex PCR panel assays. The study cohort comprised 233 allo-HCT recipients with 37…

medicine.medical_specialtyMultivariate analysisEpidemiologymedicine.medical_treatmentHematopoietic stem cell transplantationArticle03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineHumansProspective StudiesRespiratory systemRespiratory Tract InfectionsTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyOdds ratioConfidence intervalStem-cell researchVirus Diseases030220 oncology & carcinogenesisCohortVirusesRespiratory virusbusiness030215 immunologyBone marrow transplantation
researchProduct

Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantatio…

2011

Preemptive antiviral therapy strategies for active cytomegalovirus (CMV) infection occurring in allogeneic stem cell transplant recipients should be optimized to avoid overtreatment. The current study was aimed at determining whether the analysis of the kinetics of CMV DNA load in plasma may provide useful information for the therapeutic management of active CMV infection in this setting. A total of 59 consecutive patients were included in the study, of which 40 (67.8%) developed 1 (n = 21) or more (n = 19) episodes of CMV DNAemia. The need for antiviral therapy for initial or secondary episodes of CMV DNAemia could not be predicted on the basis of the CMV DNA load value in the first plasma…

AdultMaleAdolescentCongenital cytomegalovirus infectionCytomegalovirusAntiviral Agentslaw.inventionYoung AdultlawMedicineDoubling timeHumansTransplantation HomologousKinetics of CMV DNA load declineYoung adultPolymerase chain reactionAgedTransplantationbusiness.industryAntiviral therapyHematopoietic Stem Cell Transplantationvirus diseasesSelf-resolving episodes of active CMV infectionHematologyMiddle Agedmedicine.diseaseCMV doubling timeCMV DNA load in plasmaClinical trialTransplantationImmunologyPreemptive antiviral therapyCytomegalovirus InfectionsDNA ViralFemaleStem cellCytomegalovirus (CMV)businessBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
researchProduct

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

2018

OBJECTIVE Characteristics and risk factors (RFs) of invasive fungal disease (IFD) have been little studied in the setting of umbilical cord blood transplantation (UCBT). METHOD We retrospectively included 205 single-unit myeloablative UCBT recipients with a median follow-up of 64 months. RESULTS Fifty-six episodes of IFD were observed in 48 patients (23%) at a median time of 123 days after stem cell infusion. Invasive mold disease (IMD) occurred in 42 cases, 38 of them (90%) caused by invasive aspergillosis whereas invasive yeast disease (IYD) occurred in 14 cases, most of them due to candidemia (n = 12, 86%). The 5-year cumulative incidence of IFD, IMDs, and IYDs was 24% 19%, and 7%, respe…

AdultMalemedicine.medical_specialtyTransplantation ConditioningMultivariate analysisAdolescentGraft vs Host DiseaseDiseaseAspergillosisSeverity of Illness IndexGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineAnti-Infective AgentsRisk FactorsCause of DeathInternal medicinemedicineHumansPublic Health SurveillanceCumulative incidenceRetrospective Studiesbusiness.industryUmbilical Cord Blood TransplantationIncidenceHematologyGeneral MedicineMiddle Agedmedicine.diseasePatient Outcome AssessmentGraft-versus-host diseaseMycoses030220 oncology & carcinogenesisFemaleCord Blood Stem Cell TransplantationStem cellComplicationbusiness030215 immunologyEuropean Journal of Haematology
researchProduct

Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft‐versus‐host disease following alloge…

2020

Background Data have been published suggesting a bidirectional interaction between cytomegalovirus (CMV) infection and acute graft-versus-host disease (aGvHD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. Here, we hypothesized that prospective CMV DNA monitoring in stool specimens may be useful for predicting subsequent occurrence of intestinal aGvHD (IaGvHD). Methods This two-center study enrolled 121 consecutive adult patients undergoing any modality of allo-HSCT. A total of 1,009 stool specimens were collected (a median of 7 specimens/patient; range, 1-18). CMV DNA monitoring in stools and plasma was performed using real-time PCR assays. Results CMV DNA was det…

Adultmedicine.medical_specialtymedicine.medical_treatmentCytomegalovirusGraft vs Host DiseaseHematopoietic stem cell transplantationDisease030230 surgerymedicine.disease_causeGastroenterologyCytomegalovirus DNAFeces03 medical and health sciences0302 clinical medicineInternal medicineAcute graft versus host diseasemedicineHumansCumulative incidenceProspective StudiesFecesTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesCytomegalovirusViral LoadIntestinal DiseasesInfectious DiseasesCytomegalovirus InfectionsDNA ViralCohort030211 gastroenterology & hepatologybusinessTransplant Infectious Disease
researchProduct

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

2019

We analyzed the outcomes of 26 consecutive patients with acquired severe aplastic anemia (SAA) undergoing peripheral blood stem cell transplantation (PBSCT) with partial ex vivo T cell depletion with a targeted T cell dose from HLA-identical sibling donors. The median patient age was 37 years (range, 3 to 63 years). Four patients with uncontrolled pneumonia at the time of transplantation died, on days +1, +2, +21, and +26. All evaluable patients engrafted, with a median time to neutrophil recovery of 11 days (range, 10 to 14 days) and a median time to platelet recovery of 19 days (range, 8 to 53 days). Two patients had transient grade I acute graft-versus-host disease (GVHD) with skin invol…

AdultMalemedicine.medical_specialtySevere aplastic anemiaAdolescentT-LymphocytesT cellGraft vs Host DiseaseHuman leukocyte antigenSeverity of Illness IndexGastroenterologyDisease-Free SurvivalLymphocyte DepletionHLA AntigensInternal medicinemedicineHumansCumulative incidenceSiblingChildAllogeneic stem cell transplantation Ex vivo T cell depletion Matched sibling donor Severe aplastic anemiaEx vivo T cell depletionMatched sibling donorPeripheral Blood Stem Cell TransplantationTransplantationbusiness.industryHistocompatibility TestingSiblingsAnemia AplasticHematologyMiddle AgedAllograftsmedicine.diseaseSevere Aplastic AnemiaTissue DonorsAllogeneic stem cell transplantationSurvival RateTransplantationPneumoniasurgical procedures operativemedicine.anatomical_structureChild PreschoolAcute DiseasebusinessEx vivoFollow-Up StudiesBiology of Blood and Marrow Transplantation
researchProduct

Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen–Matched Sibling Transp…

2016

We analyzed the incidence, clinical characteristics, prognostic factors, and outcome of central nervous system (CNS) infections in consecutive patients with receiving umbilical cord blood transplantation (UCBT) (n = 343) or HLA-matched sibling donor stem cell transplantation (MST) (n = 366). Thirty-four CNS infections were documented at a median time of 116 days after transplantation (range, 7 to 1161). The cumulative incidence (CI) risk of developing a CNS infection was .6% at day +30, 2.3% at day +90, and 4.9% at 5 years. The 5-year CI of CNS infection was 8.2% after UCBT and 1.7% after MST (P  .001). The causative micro-organisms of CNS infections were fungi (35%), virus (32%), Toxoplasm…

Adultmedicine.medical_specialtyTime FactorsAdolescentCentral nervous systemHuman leukocyte antigenGastroenterologyYoung Adult03 medical and health sciencesCentral Nervous System Infections0302 clinical medicineHLA AntigensInternal medicinemedicineHumansCumulative incidenceAgedTransplantationbusiness.industryUmbilical Cord Blood TransplantationIncidenceSiblingsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationBacterial InfectionsHematologyMiddle Agedmedicine.diseaseTransplantationmedicine.anatomical_structureMycosesVirus DiseasesHistocompatibility030220 oncology & carcinogenesisImmunologyCord Blood Stem Cell TransplantationStem cellUnrelated DonorsbusinessToxoplasmosisEncephalitis030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Adoptive transfer of ex vivo expanded SARS‐CoV‐2‐specific cytotoxic lymphocytes: A viable strategy for COVID‐19 immunosuppressed patients?

2021

Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections is on focus of research. We evaluate herein the feasibility of expanding virus‐specific T cells (VST) against SARS‐CoV‐2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS‐CoV‐2 asymptomatic infection/negative serology, (b) SARS‐CoV‐2 symptomatic infection/positive serology, and (c) no history of SARS‐CoV‐2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 6…

CD4-Positive T-LymphocytesAdoptive cell transferviruses030230 surgerymedicine.disease_causevirus-specific T cellsAsymptomaticSARS‐CoV‐2Serology03 medical and health sciences0302 clinical medicineCOVID‐19medicineCytotoxic T cellHumansRespiratory systemthird‐party donorsCoronavirusTransplantationbusiness.industrySARS-CoV-2COVID-19Original Articlesvirus‐specific T cellsAdoptive Transferlymphocyte expansionrespiratory virusInfectious DiseasesImmunologyRespiratory virus030211 gastroenterology & hepatologyOriginal Articlethird-party donorsmedicine.symptombusinessadoptive immunotherapyEx vivo
researchProduct

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft‐ver…

2021

Sirolimus has emerged as an alternative to calcineurin inhibitors-based (CNI) graft-versus-host disease (GVHD) prophylaxis. This retrospective study compares the outcome of 133 consecutive adult patients with haematological malignancies undergoing haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCy) and mycophenolate mofetil (MMF), combined with cyclosporine A (PTCy-CsA-MMF,

medicine.medical_specialtyHaploidentical transplantationCyclophosphamidebusiness.industryUrologyMycophenolatemedicine.diseaseTransplantationGraft-versus-host diseaseSirolimusToxicityMedicineStem cellbusinessmedicine.drugeJHaem
researchProduct

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

2022

Abstract Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3–6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 …

*Pfizer-BioNTech BNT162b2Cancer ResearchCOVID-19 Vaccines*Hematological malignanciesAutologous stem cell transplantationAntibodies ViralBreakthrough SARS-CoV-2 infectionModerna mRNA-1273Cohort StudiesHematological malignancies*Moderna mRNA-1273Correlates of protection*VaccineHumansProspective StudiesVacunacióPfizer-BioNTech BNT162b2Molecular BiologyBNT162 Vaccine*Immunocompromised patients*Correlates of protectionSARS-CoV-2VaccinationHematologic diseasesCOVID-19Hematology*Breakthrough SARS-CoV-2 infectionHematologic DiseasesSARS-CoV-2 vaccinesAllogeneic stem cell transplantationVirusOncologyMalalties hematològiquesImmunocompromised patients*SARS-CoV-2 vaccines*Autologous stem cell transplantation*COVID-19Vaccine*Allogeneic stem cell transplantationJournal of Hematology &amp; Oncology
researchProduct

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Thera…

2022

Simple Summary We present the long-term results of patients receiving allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory mantle cell lymphoma (R/R MCL) in the last 25 years in Spain. We conclude that allo-SCT may be a curative option in R/R MCL with a low cumulative incidence (CI) of relapse, although non-relapse mortality (NRM) is still high, which is mainly secondary to acute graft-versus-host disease (aGVHD). Results are better for fit patients, using HLA-identical (related or unrelated) or haploidentical related donors and without previous ASCT. However, the arrival of new highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegat…

CAR-T cell therapyCancer ResearchLimfomesMantle cell lymphomaAcute graft-versus-host diseaseTransplantation of organstarget therapyacute graft-versus-host diseasemantle cell lymphomaTarget therapyTrasplantament d'òrgansgraft-versus-lymphoma effectnon-relapse mortalityOncologyNon-relapse mortalityimmune system diseaseshemic and lymphatic diseasesallogeneic stem-cell transplantationmantle cell lymphoma; allogeneic stem-cell transplantation; non-relapse mortality; acute graft-versus-host disease; graft-versus-lymphoma effect; target therapy; CAR-T cell therapyLymphomasAllogeneic stem-cell transplantationCàncerGraft-versus-lymphoma effect
researchProduct

Additional file 1 of SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

2022

Additional file 1: Table S1. Characteristics of serological assays used in the study. Table S2. Commercial PCR test available in participating centers.

researchProduct